This comprehensive review outlines the risk factors, diagnosis, and management of heparin-induced thrombocytopenia, emphasizing the critical need for clinical vigilance to reduce mortality.
Patients with or at risk for heparin-induced thrombocytopenia
Clinical vigilance is crucial for the recognition, diagnosis, and treatment of heparin-induced thrombocytopenia to reduce morbidity and mortality, particularly in patients undergoing cardiopulmonary bypass or catheterization.
Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonly, to low-molecular weight heparin. In this comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. The authors place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass or interventions in the catheterization laboratory. Clinical vigilance of this disease process is important to ensure its recognition, diagnosis, and treatment. Misdiagnosis of the syndrome, as well as misunderstanding of the disease process, continues to contribute to its morbidity and mortality.
Building similarity graph...
Analyzing shared references across papers
Benjamin Salter
Menachem M. Weiner
Muoi Trinh
Journal of the American College of Cardiology
Mount Sinai Medical Center
Building similarity graph...
Analyzing shared references across papers
Salter et al. (Sun,) conducted a review in Heparin-induced thrombocytopenia. This comprehensive review outlines the risk factors, diagnosis, and management of heparin-induced thrombocytopenia, emphasizing the critical need for clinical vigilance to reduce mortality.
www.synapsesocial.com/papers/69e93b854f237034adf83cac — DOI: https://doi.org/10.1016/j.jacc.2016.02.073
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: